Does elevated lipoprotein(a) promote atherosclerosis even when LDL cholesterol is well controlled?

Elevated lipoprotein(a) [Lp(a)] is a genetically determined, continuous contributor to atherosclerotic cardiovascular disease (ASCVD), not simply a marker that becomes irrelevant once LDL cholesterol is low. For a 57-year-old man, an Lp(a) measurement can identify residual lifetime risk that standard LDL-C results do not fully capture.

Clinical and imaging evidence

• Mendelian-randomization, prospective, and meta-analytic evidence supports a causal relationship between higher Lp(a) and coronary disease, myocardial infarction, and major adverse cardiovascular events.
• Risk is continuous. The European Atherosclerosis Society uses >50 mg/dL (125 nmol/L) as a practical clinically significant level; concentrations around 100 mg/dL (~250 nmol/L) approximately double risk.
• In treated populations, Lp(a) ≥125 nmol/L was associated with greater 10-year coronary atheroma progression, low-density plaque, and pericoronary inflammation. Each Lp(a) doubling corresponded to an additional 0.32% atheroma volume; another analysis found a 10.5% adjusted increase in low-attenuation plaque progression per 50 mg/dL increase.

Mechanistic basis

• Lp(a) is an apoB-containing particle retained in the arterial wall, where apo(a) interactions with extracellular-matrix proteins may augment retention. It delivers cholesterol and oxidized phospholipids (OxPL), promoting endothelial activation, monocyte recruitment, foam-cell formation, and plaque destabilization.
• Human translational work links high Lp(a) to arterial-wall inflammation. Lp(a) stimulates monocyte TNF-α, IL-1β, and IL-6 production; OxPL removal or inactivation substantially attenuates this response.
• Apo(a), a plasminogen homolog, competes at fibrin and cellular binding sites and reduces tPA-mediated plasmin generation, supporting impaired endogenous fibrinolysis.

Clinical implications

• LDL-C lowering remains essential but does not eliminate Lp(a)-associated residual risk. Current guidance supports measuring Lp(a) at least once in adulthood and intensifying control of all modifiable risks.
• Selective Lp(a)-lowering has not yet been proven to reverse plaque or reduce cardiovascular events.

Bottom line

• The claim is well supported: elevated Lp(a) promotes ASCVD through convergent atherogenic, inflammatory, and antifibrinolytic pathways, including when LDL-C is well controlled.